SHANGHAI LABWAY CLINICAL Competitors and Similar CompaniesClear all

SHANGHAI LABWAY CLINICAL's competitors and similar companies include Transasia Bio-Medicals, Agappe Diagnostics, Autobio Diagnostics and Ortho Clinical Diagnostics US.

	SHANGHAI LABWAY CLINICAL SHANGHAI LABWAY CLINICAL (上海兰卫医学检验所股份有限公司) is a healthcare company that specializes in medical inspection services for the clinics and laboratory sectors.	Transasia Bio-Medicals Transasia Bio-Medicals is a developer and manufacturer of healthcare products.	Agappe Diagnostics Agappe Diagnostics is a company that produces clinical chemistry reagents and distributes in-vitro diagnostics equipment.	Autobio Diagnostics Autobio Diagnostics (奧託生物診斷有限公司) is a manufacturer and supplier of medical diagnostics products.	Ortho Clinical Diagnostics US Ortho Clinical Diagnostics US is a company specializing in in vitro diagnostics.
Founding Date	Founding Date 1993	Founding Date 1979	Founding Date 1994	Founding Date 1998	Founding Date 1994
Type	Type Public	Type Subsidiary	Type Private	Type Public	Type Subsidiary
Tags	Tags Healthcare medical devices medical diagnostics	Tags Healthcare medical devices medical diagnostics	Tags Healthcare medical devices medical diagnostics	Tags Healthcare medical devices medical diagnostics	Tags Healthcare medical devices medical diagnostics
Locations	Locations HQ	Locations HQ	Locations Kochi, IN HQ Bengaluru, IN Kolkata, IN Mumbai, IN Nellad, IN New Delhi, IN Cham, CH	Locations Zheng Zhou Shi, CN HQ	Locations Raritan, US HQ Rochester, US
Employees	Employees N/A	Employees 2,0351% increase	Employees 1,1652% increase	Employees 5,773	Employees 1,650
Valuation ($)	Valuation ($) 568.9 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 3.6 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ¥1.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥4.1b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods ¥1.4b (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥1.5b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit ¥378.2m (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit ¥2.7b (FY, 2025)	Gross profit N/A
Net income	Net income (¥98.6m) (FY, 2024)	Net income N/A	Net income N/A	Net income ¥1.1b (FY, 2025)	Net income N/A